88419
document
Efficacy and safety of triamcinolone acetonide aqueous nasal spray in patients with seasonal allergic rhinitis . BACKGROUND In order to accommodate increasing patient preferences a new aqueous formulation of triamcinolone acetonide nasal spray was developed for the relief of symptoms associated with seasonal and perennial allergic rhinitis . OBJECTIVE This multicenter , randomized , double-blind study was designed to compare the efficacy and safety of once-daily triamcinolone acetonide aqueous nasal spray ( 220 micrograms/day ) with placebo in relieving the symptoms of seasonal allergic rhinitis due to ragweed . METHODS One hundred forty patients received either a once daily 220-microgram dose of triamcinolone acetonide aqueous nasal spray or placebo for 2 weeks . Patients evaluated the severity of seasonal allergic rhinitis symptoms daily for 2 weeks according to a 4-point scale ( 0 = absent , 1 = mild , 2 = moderate , 3 = severe ) . Physician and patient global evaluations of overall treatment effectiveness were assessed at the end of the treatment period . RESULTS Patients receiving triamcinolone acetonide aqueous nasal spray , 220 micrograms/day , had significantly ( P < .05 ) greater improvements in all rhinitis symptoms at weeks 1 and 2 and overall for the 2-week treatment period compared with the placebo group . A significant ( P = .006 ) improvement in the nasal index occurred as early as 12 hours after the first dose of triamcinolone acetonide aqueous nasal spray . Both patients and physicians reported a greater overall improvement in symptoms for the triamcinolone acetonide aqueous nasal spray group . There were no differences between the two treatment groups in the incidence of adverse events . CONCLUSIONS This study confirmed that a 220-microgram dose of triamcinolone acetonide aqueous nasal spray , administered once daily for 2 weeks , is well tolerated and reduces effectively the severity of symptoms of seasonal allergic rhinitis due to ragweed .
88420
Intervention_Pharmacological
triamcinolone acetonide aqueous nasal spray
88421
Intervention_Pharmacological
of triamcinolone acetonide
88422
Intervention_Pharmacological
triamcinolone acetonide aqueous nasal spray
88423
Intervention_Control
placebo
88424
Intervention_Pharmacological
triamcinolone acetonide aqueous nasal spray
88425
Intervention_Control
placebo
88426
Outcome_Physical
seasonal allergic rhinitis
88427
Outcome_Physical
seasonal allergic rhinitis symptoms
88428
Outcome_Physical
improvements
88429
Outcome_Physical
rhinitis symptoms
88430
Outcome_Physical
improvement in the nasal index occurred
88431
Outcome_Adverse-effects
adverse events .
88432
Outcome_Physical
reduces effectively the severity of symptoms of seasonal allergic rhinitis due to ragweed .
88433
Participant_Condition
seasonal allergic rhinitis
88434
Participant_Condition
seasonal allergic rhinitis
88435
Participant_Sample-size
One hundred forty
88436
Participant_Condition
seasonal allergic rhinitis